Compositions containing aromatic aldehydes and their use in treatments
Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.
1. A composition comprising (1) an effective skin-condition alleviating amount of an ingredient selected from the group consisting of 2-ethoxybenzaldehyde, 4-allyloxybenzaldehyde, 4-ethoxybenzaldehyde, 4-propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde; and (2) a pharmaceutically or cosmetically acceptable topical carrier, wherein the skin-condition is selected from the group consisting of skin inflammation, aging, sunburn microbial infection, psoriasis, acne, dandruff, hair loss, poison ivy, rosacea, and eczema.
2. The composition of claim 1 in a sustained release dosage form.
3. The composition of claim 1 , wherein the first active ingredient is 4-ethoxybenzaldehyde.
4. The composition of claim 1 , wherein the pharmaceutically or cosmetically acceptable topical carrier is a lotion.
5. The composition of claim 1 , wherein the pharmaceutically or cosmetically acceptable topical carrier is a cream.
6. A method for alleviating symptoms of a skin condition, comprising topically administering to said affected skin an effective amount of the composition of claim 1 to alleviate said symptoms, wherein the skin condition is selected from the group consisting of skin inflammation, aging, sunburn microbial infection, psoriasis, acne, dandruff, hair loss, poison ivy, rosacea, and eczema.
7. The composition of claim 1 , wherein the effective skin-condition alleviating amount of the first active ingredient selected from the group consisting of 2-ethoxybenzaldehyde, 4-allyloxybenzaldehyde, 4-ethoxybenzaldehyde, 4-propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde is between 0.001% to 20% by weight.
8. The composition of claim 3 , wherein the effective skin-condition alleviating amount of 4-ethoxybenzaldehyde is between 1.0% and 10% by weight.
9. The composition of claim 8 , wherein the effective skin-condition alleviating amount of 4-ethoxybenzaldehyde is 1.0% by weight.
10. A transdermal composition, comprising a transdermal preparation of (1) an effective skin-condition alleviating amount of an ingredient selected from the group consisting of 2-ethoxybenzaldehyde, 4-allyloxybenzaldehyde, 4-ethoxybenzaldehyde, 4-propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde; and (2) a pharmaceutically or cosmetically acceptable carrier, wherein the skin-condition is selected from the group consisting of skin inflammation, aging, sunburn microbial infection, psoriasis, acne, dandruff, hair loss, poison ivy, rosacea, and eczema.
11. The trans dermal composition of claim 10 in a sustained release dosage form.
12. The trans dermal composition of claim 10 , wherein the first active ingredient is 4-ethoxybenzaldehyde.
13. The transdermal composition of claim 10 , wherein the pharmaceutically or cosmetically acceptable carrier is a lotion.
14. The transdermal composition of claim 10 , wherein the pharmaceutically or cosmetically acceptable carrier is a cream.
15. A method for treating a patient with a skin condition, comprising administering to said patient an effective skin-condition alleviating amount of the transdermal composition of claim 10 , wherein the skin-condition is selected from the group consisting of skin inflammation, aging, sunburn microbial infection, psoriasis, acne, dandruff, hair loss, poison ivy, rosacea, and eczema.
16. The transdermal composition of claim 10 , wherein the effective skin-condition alleviating amount of the first active ingredient selected from the group consisting of 2-ethoxybenzaldehyde, 4-allyloxybenzaldehyde, 4-ethoxybenzaldehyde, 4-propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde is between 0.001% to 20% by weight.
17. The transdermal composition of claim 12 , wherein the effective skin-condition alleviating amount of 4-ethoxybenzaldehyde is between 1.0% and 10% by weight.
18. The transdermal composition of claim 17 , wherein the effective skin-condition alleviating amount of 4-ethoxybenzaldehyde is 1.0% by weight.